| 17 |
17: Altered expression of AHR/ARNT pathway-dependent genes |
80: Up Regulation, CYP1A1 |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 16 |
17: Altered expression of AHR/ARNT pathway-dependent genes |
317: Altered, Cardiovascular development/function |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 11 |
12: AchE Inhibition |
10: ACh Synaptic Accumulation |
Nov 29, 2016 |
Sep 10, 2023 |
4 AOPs
|
| 9 |
8: Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity |
179: Decrease, Fatty acid β-oxidation |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 359 |
386: Neuronal network function, Decreased |
341: Impairment, Learning and memory |
Nov 29, 2016 |
Jul 15, 2022 |
6 AOPs
|
| 360 |
387: Binding of agonist, NMDARs |
388: Overactivation, NMDARs |
Nov 29, 2016 |
Nov 29, 2016 |
None
|
| 361 |
388: Overactivation, NMDARs |
389: Increased, Intracellular Calcium overload |
Nov 29, 2016 |
Sep 10, 2023 |
4 AOPs
|
| 362 |
389: Increased, Intracellular Calcium overload |
177: Increase, Mitochondrial dysfunction |
Nov 29, 2016 |
Nov 29, 2016 |
2 AOPs
|
| 363 |
177: Increase, Mitochondrial dysfunction |
55: Cell injury/death |
Nov 29, 2016 |
Nov 29, 2016 |
4 AOPs
|
| 364 |
55: Cell injury/death |
352: N/A, Neurodegeneration |
Nov 29, 2016 |
Sep 10, 2023 |
2 AOPs
|
| 365 |
55: Cell injury/death |
188: Neuroinflammation |
Nov 29, 2016 |
Jul 15, 2022 |
3 AOPs
|
| 348 |
381: BDNF, Reduced |
382: Aberrant, Dendritic morphology |
Nov 29, 2016 |
Nov 29, 2016 |
1 AOP
|
| 358 |
385: Synaptogenesis, Decreased |
386: Neuronal network function, Decreased |
Nov 29, 2016 |
May 25, 2018 |
2 AOPs
|
| 357 |
383: Reduced, Presynaptic release of glutamate |
385: Synaptogenesis, Decreased |
Nov 29, 2016 |
Nov 29, 2016 |
1 AOP
|
| 356 |
382: Aberrant, Dendritic morphology |
385: Synaptogenesis, Decreased |
Nov 29, 2016 |
Nov 29, 2016 |
1 AOP
|
| 355 |
55: Cell injury/death |
385: Synaptogenesis, Decreased |
Nov 29, 2016 |
Nov 29, 2016 |
1 AOP
|
| 354 |
381: BDNF, Reduced |
383: Reduced, Presynaptic release of glutamate |
Nov 29, 2016 |
Nov 29, 2016 |
1 AOP
|
| 353 |
381: BDNF, Reduced |
55: Cell injury/death |
Nov 29, 2016 |
Nov 29, 2016 |
2 AOPs
|
| 352 |
373: Formation, Pro-mutagenic DNA Adducts |
384: Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci |
Nov 29, 2016 |
Nov 29, 2016 |
None
|
| 351 |
376: Increased, Induced Mutations in Critical Genes |
384: Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci |
Nov 29, 2016 |
Nov 29, 2016 |
None
|
| 350 |
384: Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci |
378: Tumorigenesis, Hepatocellular carcinoma |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 336 |
307: Increase, Vitellogenin synthesis in liver |
220: Increase, Plasma vitellogenin concentrations |
Nov 29, 2016 |
Jun 24, 2024 |
3 AOPs
|
| 347 |
52: Decreased, Calcium influx |
381: BDNF, Reduced |
Nov 29, 2016 |
Jun 13, 2018 |
2 AOPs
|
| 346 |
376: Increased, Induced Mutations in Critical Genes |
378: Tumorigenesis, Hepatocellular carcinoma |
Nov 29, 2016 |
Nov 30, 2016 |
1 AOP
|
| 345 |
373: Formation, Pro-mutagenic DNA Adducts |
378: Tumorigenesis, Hepatocellular carcinoma |
Nov 29, 2016 |
Nov 29, 2016 |
1 AOP
|